First in-human trial using CRISPR/CASP 12 for gene editing in sickle cell disease
Physicians shares insights about screening, supportive care and potential therapies in development
A 12-year-old patient and others in clinical trial are cured of sickle cell disease thanks to half-match donors
The short answer from Rabi Hanna, MD
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
The short answer from Rabi Hanna, MD
Percutaneous vertebral augmentation proves safe and effective
Get to know Dr. Rabi Hanna
Patient discharged 18 days later
Transplant-related mortality, relapse rates are low